Janux Therapeutics (NASDAQ:JANX) Stock Price Down 7.2% – What’s Next?

Janux Therapeutics, Inc. (NASDAQ:JANX)’s share price fell 7.2% during mid-day trading on Thursday . The company traded as low as $18.24 and last traded at $17.9370. 265,496 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 1,103,910 shares. The stock had previously closed at $19.33.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on JANX. Truist Financial restated a “buy” rating and issued a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Monday, July 20th. TD Cowen upgraded Janux Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wolfe Research upgraded Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research note on Monday, August 24th. Finally, Stifel Nicolaus set a $35.00 price target on shares of Janux Therapeutics in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.46.

Janux Therapeutics Trading Down 7.0%

The business has a 50 day moving average of $16.87 and a 200-day moving average of $15.18. The stock has a market cap of $1.10 billion, a PE ratio of -10.97 and a beta of 2.53.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to the consensus estimate of $19.07 million. Research analysts expect that Janux Therapeutics, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Trading of Janux Therapeutics

A number of large investors have recently bought and sold shares of the business. WINTON GROUP Ltd raised its holdings in shares of Janux Therapeutics by 31.8% in the second quarter. WINTON GROUP Ltd now owns 90,300 shares of the company’s stock valued at $1,387,000 after buying an additional 21,800 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Janux Therapeutics in the 2nd quarter valued at about $174,000. California State Teachers Retirement System raised its stake in Janux Therapeutics by 2,014.3% during the 2nd quarter. California State Teachers Retirement System now owns 782,316 shares of the company’s stock valued at $12,016,000 after acquiring an additional 745,315 shares during the last quarter. Raiffeisen Bank International AG raised its stake in Janux Therapeutics by 9.1% during the 2nd quarter. Raiffeisen Bank International AG now owns 60,000 shares of the company’s stock valued at $920,000 after acquiring an additional 5,000 shares during the last quarter. Finally, AXQ Capital LP lifted its position in Janux Therapeutics by 109.0% during the 2nd quarter. AXQ Capital LP now owns 47,508 shares of the company’s stock worth $730,000 after acquiring an additional 24,777 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.